![Jeffrey Conroy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jeffrey Conroy
Directeur Général chez
Embody, Inc.
Profil
Jeffrey Conroy is the Chairman & Chief Executive Officer and founder of Embody, Inc. which is founded in 2014.
He is currently an Independent Director at Cingulate Therapeutics LLC, Virginia Biosciences Health Research Corp., and Cingulate Works, Inc. He was formerly the Chairman of Virginia Biotechnology Association from 2014 to 2017.
He was also a Managing Director at Windward Investments LLC from 2012 to 2019 and Adjuvant Partners LLC from 2000 to 2012.
Additionally, he was the Head-Corporate Development at Específicos Stendhal SA de CV from 2012 to 2019.
He holds an undergraduate degree from Providence College.
Postes actifs de Jeffrey Conroy
| Sociétés | Poste | Début |
|---|---|---|
Cingulate Therapeutics LLC
 Cingulate Therapeutics LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that focuses on develops attention deficit/hyperactivity disorder products | Directeur/Membre du Conseil | 31/05/2018 |
Embody, Inc.
 Embody, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes implantable medical devices | Directeur Général | 01/07/2015 |
Cingulate Works, Inc.
 Cingulate Works, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals for the treatment of central nervous system and neurobiological disorders | Directeur/Membre du Conseil | 01/05/2018 |
Virginia Biosciences Health Research Corp.
 Virginia Biosciences Health Research Corp. Virginia Biosciences Health Research Corp., operating as Catalyst, is a nonprofit organization established by the general assembly and funded by the commonwealth and five public research universities. The non-profit company is based in Richmond, VA. The company advances economic development by fostering collaborations between research universities and the life sciences industry to address unmet medical and life science needs, improve human health, and create jobs. Catalyst accelerates translational bioscience research and commercialization through strategic initiatives and provides competitive grant funding to support collaborative projects involving at least two research universities and an industry partner. Funded projects focus on technologies with market potential in areas such as bioinformatics, medical informatics, point-of-care diagnostics, drug discovery, and delivery. Grant applications undergo a multi-step review process, and funding is milestone-based, requiring measurable goals, matching funds, and progress reporting. The company emphasizes strong project management, scientific merit, commercialization plans, and impartial evaluation of grant applications. | Directeur/Membre du Conseil | - |
Anciens postes connus de Jeffrey Conroy
| Sociétés | Poste | Fin |
|---|---|---|
| CINGULATE INC. | Directeur/Membre du Conseil | 05/01/2023 |
| ODYSSEY HEALTH, INC. | Directeur/Membre du Conseil | 04/01/2023 |
Windward Investments LLC
 Windward Investments LLC Financial ConglomeratesFinance Functions as an investment holding company | Corporate Officer/Principal | 01/12/2019 |
Específicos Stendhal SA de CV
 Específicos Stendhal SA de CV Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01/01/2019 |
Virginia Biotechnology Association
 Virginia Biotechnology Association Miscellaneous Commercial ServicesCommercial Services Promotes biotechnology industry | Président | 30/08/2017 |
Formation de Jeffrey Conroy
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
5
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Cingulate Therapeutics LLC
Cingulate Therapeutics LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that focuses on develops attention deficit/hyperactivity disorder products | Health Technology |
Odyssey Health, Inc.
 Odyssey Health, Inc. Medical SpecialtiesHealth Technology Develops heart monitoring and screening devices | Health Technology |
Providence College
 Providence College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Virginia Biotechnology Association
Virginia Biotechnology Association Miscellaneous Commercial ServicesCommercial Services Promotes biotechnology industry | Commercial Services |
Específicos Stendhal SA de CV
Específicos Stendhal SA de CV Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Windward Investments LLC
Windward Investments LLC Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Embody, Inc.
Embody, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes implantable medical devices | Health Technology |
Adjuvant Partners LLC | |
Virginia Biosciences Health Research Corp.
Virginia Biosciences Health Research Corp. Virginia Biosciences Health Research Corp., operating as Catalyst, is a nonprofit organization established by the general assembly and funded by the commonwealth and five public research universities. The non-profit company is based in Richmond, VA. The company advances economic development by fostering collaborations between research universities and the life sciences industry to address unmet medical and life science needs, improve human health, and create jobs. Catalyst accelerates translational bioscience research and commercialization through strategic initiatives and provides competitive grant funding to support collaborative projects involving at least two research universities and an industry partner. Funded projects focus on technologies with market potential in areas such as bioinformatics, medical informatics, point-of-care diagnostics, drug discovery, and delivery. Grant applications undergo a multi-step review process, and funding is milestone-based, requiring measurable goals, matching funds, and progress reporting. The company emphasizes strong project management, scientific merit, commercialization plans, and impartial evaluation of grant applications. | |
Cingulate Works, Inc.
Cingulate Works, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals for the treatment of central nervous system and neurobiological disorders | Health Technology |
Cingulate, Inc.
 Cingulate, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Choisissez Zonebourse 
